Abbott Laboratories (ABT) Earnings
Abbott Laboratories is expected to report next earnings on July 16, 2026 (in NaN days), with a consensus EPS estimate of $1.28. ABT has beaten EPS estimates in 5 of its last 12 reported quarters (average surprise +0.2% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 16, 2026 | $1.14 | $1.15 | +0.9% | $11.2B | +1.5% |
| Jan 22, 2026 | $1.50 | $1.50 | +0.0% | $11.5B | -2.9% |
| Oct 15, 2025 | $1.30 | $1.30 | +0.0% | $11.4B | -0.2% |
| Jul 17, 2025 | $1.26 | $1.26 | +0.0% | $11.1B | +0.5% |
| Apr 16, 2025 | $1.07 | $1.09 | +1.9% | $10.4B | -0.5% |
| Jan 22, 2025 | $1.34 | $1.34 | +0.0% | $11.0B | -0.5% |
| Oct 16, 2024 | $1.20 | $1.21 | +0.8% | $10.6B | +0.8% |
| Jul 18, 2024 | $1.10 | $1.14 | +3.6% | $10.4B | +0.1% |
| Apr 17, 2024 | $0.95 | $0.98 | +2.6% | $10.0B | +0.8% |
| Jan 24, 2024 | $1.19 | $1.19 | +0.0% | $10.2B | +0.6% |
| Oct 18, 2023 | $1.10 | $1.14 | +3.6% | $10.1B | +5.5% |
| Jul 20, 2023 | $1.04 | $1.08 | +3.8% | $10.0B | +2.9% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · April 16, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Pipeline achievements in medical device business: Earlier than planned approval and launch of two new PFA catheters, completion of patient enrollment in catalyst left atrial appendage device trial, initiation of development activities for implantable extravascular ICD product, announcement of positive results from randomized control trial on type 2 diabetes and Libre. Preparing to initiate patient enrollment in several clinical trials in second half of year with pipeline of new technologies including balloon expandable TAVR valve, leadless conduction system pacing device, mitral replacement valve, peripheral IVL device, wearable continuous lactate monitoring sensor. - Completion of acquisition of Exact Sciences, adding new high-growth business to portfolio, forecasting $3 billion incremental sales in 2026 and accelerating long-term sales growth rate. - First quarter results aligned with expectations, with adjusted earnings per share of $1.15, consistent with guidance despite financing costs and respiratory season impact. Confidence in acceleration of growth in second half with key drivers including executing growth strategy in nutrition, accelerating growth in electrophysiology and core lab diagnostics, strong performance in EPD and medical devices portfolio, and integrating ExactSciences.
Guidance
- Full year 2026 sales growth outlook on comparable basis is 6.5% to 7.5%. - New adjusted earnings per share guidance range midpoint of $5.48 reflects 20 cents of dilution related to Exact Sciences acquisition. - First quarter sales increased 3.7% on comparable basis, adjusted earnings per share $1.15 grew 6% compared to prior year. - Foreign exchange had favorable year-over-year impact of 4% on first quarter sales, expect favorable impact of approximately 1% on full-year reported sales, relatively neutral impact on second quarter sales. - Forecast adjusted earnings per share for second quarter of $1.25 to $1.31.
Segment performance
Diagnostics: Sales increased 2% on comparable basis. Core lab diagnostics grew 3% in US, Europe, Latin America. Rapid and molecular diagnostic sales declined 10% due to weaker respiratory season. Cancer diagnostics sales grew 13% with mid-teens growth in Cologuard and high teens in international markets. Nutrition: Sales slightly ahead of expectations, lower sales volumes last year and strategic pricing actions, but volume growth beginning to follow pricing actions. EPD: Sales increased 9% with broad-based growth in Latin America and Asia Pacific regions. Medical devices: Sales grew 8.5%. Cardiovascular device businesses led growth, including 13% growth in electrophysiology with two pulse-fueled ablation catheter launches, 13% growth in rhythm management, 12% growth in heart failure, and CGM sales $2 billion with 7.5% growth, expecting return to double-digit growth in Q2.
Risks & headwinds
- Economic, competitive, governmental, technological, and other factors that may affect Abbott's operations as discussed in Item 1A, Risk Factors, to annual report on Form 10-K for the year ended December 31st, 2025. - Impact of lower respiratory season on rapid and molecular diagnostic sales, uncertainty regarding future respiratory seasons and ability to predict and prepare for them. - Potential impact of oil costs, freight rates, and supply chain issues related to conflicts like the Middle East conflict, though currently monitoring and teams in place to mitigate.
Analyst Q&A
Q: David Roman from Goldman Sachs asked about updated guidance, guidance philosophy, and extent of outlook de-risking and contemplating downside risks.
A: Philosophy is to provide clear and transparent breakdown of performance, conservative side on respiratory season impact, key drivers of sales forecast include sustaining growth in MedTech and pharma, trajectory changing in diagnostics and nutrition, and integration of ExactSciences.
Q: Robbie Marcus from JP Morgan followed up on comparable growth and organic growth deceleration, asking about managing it, one-time vs sustainable, and pressure points.
A: Rolled in ExactSciences on comparable basis for full visibility, strong on MedTech and pharma growth, focused on trajectory-changing businesses like diagnostics and nutrition.
Q: Larry Beagleson from Wells Fargo asked about CGM, prescription trends, Libre growth, and timing of type 2 non-insulin and lactate sensor.
A: Bullish on CGM market, 70-80 million people should be on CGMs globally, 10-12 million currently, catalysts like reimbursement, international expansion, innovation, expected approval of dual analyte system in second half of year.
Q: Vijay Kumar from Evercore ISI asked about ExactSciences, plans for Cologuard growth, international angle, and upside in guidance.
A: Integration of ExactSciences going well, Cologuard has high demand, underpenetrated in US and internationally, rescreens and CareGap programs contributing to growth.
Q: Matthew Taylor from Jefferies asked about trends in structural heart and left atrial appendage closure, impact of competitor study.
A: Moved left atrial appendage closure device to electrophysiology business, structural heart business doing well with high single-digit growth expected, waiting for own trial results.
Q: Travis Steed from B of A Securities asked about nutrition business, volume recovery, portfolio management.
A: Nutrition business seeing volume recovery with price reset, teams focused on ongoing work, constantly evaluating portfolio for value creation.
Q: Joanne Wunsch from Citi asked about macro issues, Middle East conflict impact on business, oil and resin costs, patient volumes, reimbursement.
A: Abbott built to withstand events, monitoring oil costs and supply chain, minimal impact seen in Q1, more about getting product into region.
Q: Josh Jennings from TD Cowan asked about EP franchise, Volt launch internationally and in US, EP market growth.
A: EP franchise doing well with double-digit growth, Volt and Tactiflex Dura launches in limited market release phase, favorable feedback, expecting acceleration in growth.
Q: Marie Thibault from BTIG asked about core lab business trajectory by geography.
A: China CoreLab sales flat in Q1, lapping headwinds, US CoreLab with high renewal rates and share gains, Europe CoreLab business doing mid to high single digits reliably